PD-1 / PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Se han encontrado 148 productos para "PD-1 / PD-L1".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sugemalimab
CAS:Sugemalimab, Anti-PD-L1 mAb, induces ADCC, for EGFR/ALK-negative metastatic NSCLC, solid tumors, and lymphoma research.Pureza:95% - 95%Forma y color:Transparent LiquidToripalimab
CAS:Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.Pureza:95% - 95.2% (SDS-PAGE); 96.8% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:147.29 kDaGilvetmab
CAS:Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.Pureza:95% - 97.9% (SDS-PAGE); 97.4% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:147.95 kDaAnti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) detects phosphorylated PD-1 by WB and flow cytometry.Pureza:95% - 97.3% (SDS-PAGE); 96.9% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:146.24 kDaAnti-Mouse PD-1 Antibody (S-5001)
Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.Forma y color:Odour LiquidVisugromab
CAS:Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15.Pureza:95% - 98.8% (SDS-PAGE); 97.5% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:144.50 kDaIvonescimab
CAS:Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).Pureza:95% - >95.0% (SDS-PAGE); 98.99% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:201.12 kDaGeptanolimab
CAS:Geptanolimab (CBT-501) is a humanized IgG4κ antibody against PD-1, blocking PD-L1/PD-L2 binding to reactivate T cell activity.Pureza:95% - 99.5% (SDS-PAGE); 97.6% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:144.14 kDaReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Pureza:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Forma y color:Transparent LiquidPeso molecular:144.16 kDaCosibelimab
CAS:Cosibelimab, a fully human monoclonal antibody, blocks PD-L1, enabling ADCC and CDC against cancer cells.Forma y color:LiquidTagitanlimab
CAS:Tagitanlimab, Humanized anti-PD-L1 mAb, blocks PD-L1-PD-1 interaction, for nasopharyngeal carcinoma (NPC) research.Pureza:95% - 95%Forma y color:Transparent LiquidPucotenlimab
CAS:Pucotenlimab (HX008) is an anti-PD-1 mAb that blocks PD-1/PD-L1/2 interactions, restoring immune function against solid tumours.Pureza:95%Forma y color:LiquidPeso molecular:144.77 kDaLesabelimab
CAS:Lesabelimab is an anti-CD274 monoclonal antibody; CD274 inhibits anti-tumor immunity by binding PDCD1.Pureza:97.8% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.8% (SDS-PAGE); 95.1% (SEC-HPLC)Forma y color:LiquidPeresolimab
CAS:Peresolimab is a humanized antibody targeting PD-1, potentially stimulating immune inhibitory pathways for autoimmune disease research.Pureza:95% - 97.8% (SDS-PAGE); 99.3% (SEC-HPLC)Forma y color:LiquidPeso molecular:145.14 kDaRulonilimab
CAS:Rulonilimab is a fully human mAb targeting PD-1 that restores T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway, commonly used in combination therapy research for HCC.Forma y color:LiquidVudalimab
CAS:Vudalimab is a bispecific antibody inhibiting PD-1 and CTLA-4 for tumor-targeted T cell activation.Pureza:98.93%Forma y color:Transparent LiquidRosnilimab
CAS:Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.Pureza:95% - 98.9% (SDS-PAGE); 98.7% (SEC-HPLC)Forma y color:LiquidPeso molecular:146.57 kDaAcasunlimab
CAS:Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.Forma y color:LiquidVolrustomig
CAS:Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.Forma y color:LiquidAcrixolimab
CAS:Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].Pureza:98%Forma y color:Liquid
